In the study by Chekmasova et al. [31], SCID-Beige mice, injected IP with human OV-CAR3 tumor cells and then treated either IV or IP with MUC16CAR T cells, showed significantly improved survival compared to the control mice, which were either untreated or treated with CAR-T cells targeting the irrelevant antigen CD19. The gene discussed is CD19; the disease is neoplasm.